Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats

British Journal of Pharmacology

Volumn 169, Issue 5, 2013, Pages 1048-1057

  Apaijai, Nattayaporn ^a   Pintana, Hiranya ^a   Chattipakorn, Siriporn C ^a,b   Chattipakorn, Nipon ^a,b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

cardiac function; high fat diet; insulin resistance; sitagliptin; vildagliptin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; SITAGLIPTIN; VILDAGLIPTIN; ADAMANTANE; CARDIOTONIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; MALONALDEHYDE; NITRILE; PYRAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC DYSFUNCTION; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG EFFICACY; HEART DISEASE; HEART MITOCHONDRION; HEART PROTECTION; HEART RATE VARIABILITY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC PARAMETERS; NONHUMAN; ORGANELLE SHAPE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; WEIGHT GAIN; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANALYSIS; ANIMAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HEART; HEART RATE; LIPID DIET; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CARDIOTONIC AGENTS; CHOLESTEROL; DIET, HIGH-FAT; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HEART; HEART RATE; INSULIN; INSULIN RESISTANCE; MALE; MALONDIALDEHYDE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, HEART; NITRILES; OBESITY; OXIDATIVE STRESS; PYRAZINES; PYRROLIDINES; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TRIAZOLES;

EID: 84879030222     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12176     Document Type: Article

References (34)

1. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A, (2004). Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89: 2078-2084.
2. Apaijai N, Pintana H, Chattipakorn SC, Chattipakorn N, (2012). Cardioprotective effects of metformin and vildagliptin in adult rats with insulin resistance induced by a high-fat diet. Endocrinology 153: 3878-3885.
3. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM, (2005). Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151.
4. Briand F, Thieblemont Q, Burcelin R, Sulpice T, (2012). Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Diabetes Obes Metab 14: 662-665.
5. Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, et al. (2005). Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 315: 688-695.
6. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635.
7. Chattipakorn N, Incharoen T, Kanlop N, Chattipakorn S, (2007). Heart rate variability in myocardial infarction and heart failure. Int J Cardiol 120: 289-296.
8. Chen B, Moore A, Escobedo LV, Koletsky MS, Hou D, Koletsky RJ, et al. (2011). Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats. Exp Biol Med (Maywood) 236: 309-314.
9. Chinda K, Palee S, Surinkaew S, Phornphutkul M, Chattipakorn S, Chattipakorn N, (2012). Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int J Cardiol (in press). doi: 10.1016/j.ijcard.2012.01.011
10. Coletta DK, Mandarino LJ, (2011). Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. Am J Physiol Endocrinol Metab 301: E749-E755.
11. Dobrian AD, Ma Q, Lindsay JW, Leone KA, Ma K, Coben J, et al. (2011). Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab 300: E410-E421.
12. Dong F, Li Q, Sreejayan N, Nunn JM, Ren J, (2007). Metallothionein prevents high-fat diet induced cardiac contractile dysfunction: role of peroxisome proliferator activated receptor gamma coactivator 1alpha and mitochondrial biogenesis. Diabetes 56: 2201-2212.
13. Flock G, Baggio LL, Longuet C, Drucker DJ, (2007). Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56: 3006-3013.
14. Goncalves A, Leal E, Paiva A, Teixeira Lemos E, Teixeira F, Ribeiro CF, et al. (2012). Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 14: 454-463.
15. Incharoen T, Thephinlap C, Srichairatanakool S, Chattipakorn S, Winichagoon P, Fucharoen S, et al. (2007). Heart rate variability in beta-thalassemic mice. Int J Cardiol 121: 203-204.
16. Kleppinger EL, Helms K, (2007). The role of vildagliptin in the management of type 2 diabetes mellitus. Ann Pharmacother 41: 824-832.
17. Kraegen EW, Cooney GJ, Turner N, (2008). Muscle insulin resistance: a case of fat overconsumption, not mitochondrial dysfunction. Proc Natl Acad Sci U S A 105: 7627-7628.
18. Kumfu S, Chattipakorn S, Chinda K, Fucharoen S, Chattipakorn N, (2012). T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol 88: 535-548.
19. Lenski M, Kazakov A, Marx N, Bohm M, Laufs U, (2011). Effects of DPP-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 51: 906-918.
20. McCann JD, Margolis TP, Wong MG, Kuppermann BD, Luckie AP, Schwartz DM, et al. (1995). A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis. Am J Ophthalmol 120: 219-226.
21. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
22. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. (2005). Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90: 4888-4894.
23. Matsui T, Nishino Y, Takeuchi M, Yamagishi S, (2011). Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 63: 383-388.
24. Ouwens DM, Boer C, Fodor M, de Galan P, Heine RJ, Maassen JA, et al. (2005). Cardiac dysfunction induced by high-fat diet is associated with altered myocardial insulin signalling in rats. Diabetologia 48: 1229-1237.
25. Pipatpiboon N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC, (2012). PPARgamma agonist improves neuronal insulin receptor function in hippocampus and brain mitochondria function in rats with insulin resistance induced by long term high-fat diets. Endocrinology 153: 329-338.
26. Pongchaidecha A, Lailerd N, Boonprasert W, Chattipakorn N, (2009). Effects of curcuminoid supplement on cardiac autonomic status in high-fat-induced obese rats. Nutrition 25: 870-878.
27. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP, (2008). Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 1: 153-160.
28. Pratchayasakul W, Kerdphoo S, Petsophonsakul P, Pongchaidecha A, Chattipakorn N, Chattipakorn SC, (2011). Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sci 88: 619-627.
29. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP, (2010). DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 3: 195-201.
30. Singh SK, Suresh MV, Prayther DC, Moorman JP, Rusinol AE, Agrawal A, (2008). Phosphoethanolamine-complexed C-reactive protein: a pharmacological-like macromolecule that binds to native low-density lipoprotein in human serum. Clin Chim Acta 394: 94-98.
31. Sun X, Pan H, Tan H, Yu Y, (2011). High free fatty acids level related with cardiac dysfunction in obese rats. Diabetes Res Clin Pract 95: 251-259.
32. Thummasorn S, Kumfu S, Chattipakorn S, Chattipakorn N, (2011). Granulocyte-colony stimulating factor attenuates mitochondrial dysfunction induced by oxidative stress in cardiac mitochondria. Mitochondrion 11: 457-466.
33. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P, (2011). Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 13: 366-373.
34. Yin M, Sillje HH, Meissner M, van Gilst WH, de Boer RA, (2011). Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 10: 85.